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Abstract
Background: The quality of life (QoL) of patients with lung cancer (LC) may be affected by disease-related
limitations such as patients’ functioning, the severity of symptoms, financial problems resulting along with the side
effects of the treatment. The objective of this study was to translate LC-specific QoL questionnaire EORTC QLQ-LC29
into Nepalese language for Nepalese LC patients.
Methods: In the process of translation, the European Organization for Research and Treatment of Cancer (EORTC)
translations guidelines were followed. The translated questionnaire was pilot-tested in a sample of 15 patients with
LC. Descriptive statistics were calculated with SPSS version 21.0.
Results: All steps of the EORTC translation guideline were followed successfully. Fifteen lung cancer patients were
included in the pilot study. Sixty percent were male and the mean age was 49.87 (range 21–76 years). For all items
not related to thoracic surgery, patients used the entire range of the response options from 1 to 4 and no missing
responses were observed. The highest mean (indicating a high symptom burden) was observed for the item
number. 35 (shortness of breath; Mean = 3.33, SD = 1.11) and the lowest mean for an item number. 45 (dizzy;
Mean = 1.73, SD = 0.96).
Conclusion: The Nepalese version of EORTC QLQ-LC29 is a result of a successfully conducted rigorous translation
procedure, and is highly comprehensible as well as acceptable to Nepalese LC patients. Thus, the Nepalese version
of EORTC QLQ-LC29 is ready to be used in international clinical studies as well as in Nepalese clinical practice.
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Introduction
Lung cancer (LC) is one of the commonest cancers caus-
ing a large death all over the world. The incidence of LC
was estimated to be 2.1 million, causing 1.8 million
deaths per annum [1, 2]. Furthermore, almost two-thirds
of the global LC incidence and mortality occur in lower
and middle-income countries [3]. In Nepal, cancer is
considered as one of the major non-communicable dis-
eases (NCDs) which causes significant social and
financial burden [4, 5]. The Global Burden of Disease
(GBD) Study 2017 classified tracheal, bronchus and LC
as a single group [6], the report states that the healthcare
burden and costs associated with this group of cancer
were significant on a global scale. Its five-year survival
rate is around 18%, which was found to be considerably
less than that of other foremost cancers such as breast
cancers, cervical cancers, etc. [7].
The GBD study (2017) also estimated that each year 2327
people die due to tracheal, bronchus, and lung cancer with
a mortality rate of 7.79/100,000 (global mortality = 24.65/
100,000). The estimated prevalence and incidence rates for
tracheal, bronchus and lung cancer in Nepal were 7.96
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(global prevalence = 43.76/100,000) and 7.41/100,000 popu-
lation (global incidence = 28.31/100,000) respectively. The
total burden associated with this group of cancer in Nepal
was 54,760.72 DALYs, which was 0.61% of the total burden
of diseases estimated for Nepal [6]. The histological type of
LC is poorly studied in Nepal. Currently, there are twelve
cancer hospitals provide diagnostic and treatment services
for different cancer patients including LC in Nepal. Out of
these hospitals, some are government hospitals and others
are private hospitals. Radiation therapy, chemotherapy, sur-
gery, immunotherapy, targeted therapy are available treat-
ment options for LC patients in Nepal. However, all these
services are not available in all hospitals; only few hospitals
(both private and government) out of the 12 cancer hospi-
tals provide comprehensive cancer treatment services for
different types of cancer. Patients also use traditional medi-
cines such as herbal and ayurvedic medicines for the treat-
ment of LC in Nepal. However, the exact data on the use of
traditional medicines in the treatment of LC is not
available.
In an oncology practice and research, the quality of life
(QoL) is increasingly being recognized as an essential
endpoint and has become a major determinant in decid-
ing treatment options [8, 9]. Out of many research tools
for assessing QoL in LC patients, the most often
used tool are QLQ-C30 and QLQ-LC13 module which
was developed by the European Organization for the Re-
search and Treatment of Cancer (EORTC). EORTC
QLQ-C30 questionnaire is a generic questionnaire that
assesses general QoL of all cases of malignancy [10] and
the LC-specific (EORTC QLQ-LC13) module assesses
specific symptoms related to LC and its treatments [11].
Since the QLQ-LC13 was developed and published in
1994 [11], a project which was initiated by the EORTC
to update the module to keep pace with the many
changes in diagnostics and treatment of LC. The up-
dated version is presently known as EORTC QLQ-LC29
[12], which contains a total of 29 questions that cover
new side effects related to targeted therapy and im-
munotherapy as well as a surgical subscale to be used in
patients who underwent thoracic surgery.
Native Nepalese speakers are estimated to be 11,826,
953 (i.e., 44.6% of the total population) in Nepal [13].
Around 50,000 of Nepalese language speakers are living
in India. Apart from Nepal and India, it is also spoken
by a substantial number of people living in Myanmar
and Bhutan. In total, there are 15 million native Nepal-
ese language speakers, the Nepalese language use ‘Deva-
nagari’ script when used in written form [14].
Currently, a Nepalese translation is available for the
QLQ-C30, but not for the QLQ-LC29. A Nepalese ver-
sion of LC29 would be helpful to measure QoL in pa-
tients who speak Nepalese language all around the
world. Therefore, the objective of the current study was
to translate the EORTC QLQ-LC29 into the Nepalese
language and to pilot-test the translated questionnaire in
a small sample of Nepalese LC patients.
Methods
Translation procedure
The questionnaire to be translated was the Phase 3 ver-
sion of QLQ-LC29 which has 29 items aggregated into
five multi-item scales (coughing, shortness of breath,
side-effects, existential issues related to tumor progres-
sion, and surgery-related symptoms). It also has five sin-
gle items which include coughing up blood, pain in the
chest, arm/shoulder and other parts of the body, and
weight loss. All items refer to a specific time (i.e., “dur-
ing the past week”), and are to be scored on a 4-point
Likert scale with the response options labeled “not at
all”; “a little”; “quite a bit”, and “very much”.
For the translation of the QLQ-LC29, approval was
obtained from the EORTC QoL Department. The trans-
lation followed the standard EORTC procedure, includ-
ing forward translation, reconciliation, back translation,
proofreading and pilot testing in a small sample of
the target population, whereby 15 patients are consid-
ered sufficient [15]. Figure 1 shows the flowchart of
the translation procedure of EORTC QLQ-LC29 into
the Nepalese version.
Pilot testing of the Nepalese version of the QLQ-LC-29
Procedure
After the Nepalese translation was approved by the
EORTC Translationa Unit (TU), it was pilot-tested in a
15 Nepalese patients diagnosed with lung cancer (LC) at
an oncology-based hospital situated in Province No 3 in
Nepal. The treatment available in this hospital are
chemotherapy, radiotherapy, surgery, targeted therapy,
and immunotherapy. More than 3000 patients visit this
hospital for the treatment of cancer annually.
Before the data collection for the pilot study, formal
permission was obtained from each participant and the
respondents were informed about the purpose and ob-
jectives of the study. Privacy and confidentiality were
maintained by not disclosing the name of the partici-
pants and ensuring them, that collected information was
used only for the research purpose. Patients were
handed with the Nepalese version of the QLQ-LC29
along with a self-administered questionnaire (i.e demo-
graphic questionnaire such as age, gender, ethnicity,
educational qualifications and occupation) by a re-
searcher. Patients filled out both questionnaires them-
selves. After completion, they were interviewed by the
researcher if they had any comments regarding the ques-
tionnaire to determine whether translated questionnaire
items were either difficult to answer or confusing or dif-
ficult to understand or upsetting/offensive. Patients were
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also asked whether they would have worded the question
differently.
Patient inclusion and exclusion criteria
Inclusion criteria for this study were histologically con-
firmed cases of LC diagnosed patients, active cancer
treatment, mentally fit to complete a questionnaire, able
to understand the Nepalese language and informed
consent. We have excluded those patients who were not
mentally fit to complete a questionnaire and unable to
understand the Nepalese language. There were no re-
strictions regarding gender, age, or level of education.
Statistical analysis
Descriptive statistics included counts, percentages, means
and standard deviations and were reported for age, gender,
Fig. 1 Translation procedure of EORTC QLQ-LC29 into Nepalese version
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ethnicity, education, and occupation. Qualitative data
stemming from patient interviews were listed in tabular
form. The IBM Statistical Package for the Social Sciences
(SPSS) Version 21.0 was used (IBM SPSS Statistics for
Windows, IBM Corp Armonk, NY, USA, 2017).
Ethics approval
The ethics approval was obtained from the Institutional
Review Committee (IRC) of Nobel College, Affiliated to
Pokhara University, Kathmandu, Province No. 3, Nepal
(Reference number EPY IRC 216/2018). Permission to
conduct the study at the oncology-based hospital was
also obtained from the respective Department of Med-
ical Oncology.
Results
Translation procedure
Forward translations
The EORTC QLQ LC-29 was initially translated from
English into Nepalese and a version that would be con-
ceptually and culturally as close as possible to the ori-
ginal English version of QLQ-LC-29. Two forward-
translators (FT1 and FT2), native speakers of the Nepal-
ese languages and fluent in English, provided their trans-
lations independently. FT1 is Health Economist and
Behavioral Scientist with Nepalese as the native language
and had very good command over English whereas FT2
is a Lecturer of Clinical Pharmacy working at one of the
colleges of Nepal who also is a native Nepalese speaker
and had very good command over English. Both the
translators were knowledgeable about clinical terminolo-
gies, phrases, slang, and jargon used in Nepalese and
English language.
Reconciled version
The two forward translations by FT1 and FT2 were
merged into one reconciled version by the Translation
Coordinator (TC) whose objective was to choose or
build from the two forward translations an optimal
translation of each item.
Back translations
The reconciled Nepalese questionnaire was handed over
to two back translators (BT1 and BT2), who were re-
quested to produce an English translation of the Nepalese
questionnaires in simple, comprehensible language. BT1 is
a senior consultant medical oncologist working at a cancer
hospital in Nepal who has strong command on both Eng-
lish and Nepalese language, whereas BT2 is a Nepalese
clinical pharmacist and academician working in a phar-
macy school in Malaysia with strong command in both
Nepalese and English languages. Both back-translation by
BT1 and BT2 were compared with the original English
version by TC and consultant medical oncologist and rec-
onciled into one version. A back-translation report was
then sent to EORTC for review and approval. The EORTC
Translation Coordinator sent some comments and sought
some clarifications, according to which the translations
were slightly modified.
Proofreading
The preliminary translation is then sent to a professional
proofreader by TU. After proofreading, the TU sends
the report to the TC for approval. After agreement in
wording, TU prepared the interim translation for pilot
testing.
Pilot study
Patient characteristics
The interim translated Nepalese questionnaires for the
pilot study were administered to the fifteen patients who
were diagnosed with LC. The study population consisted
of participants who were native Nepalese speakers. Med-
ical records were retrieved for the clinical status of pa-
tients and only patients who were diagnosed as LC was
included for a pilot study.
Fifteen patients were enrolled in the present study;
the mean age of the entire cohort was 49.87 (standard
deviation 16.89, range 21–76 years) (Table 1). Sixty
percent of the participant (n = 9) were male. Fifty-
three percent of the respondents have attended univer-
sity/college. All recruited patients accepted and answered
self-administered questionnaires (i.e. demographic
Table 1 Patient Characteristics (n = 15)
Respondents’ characteristics (n = 15) Frequency (%)
Age Mean ± SD: 49.87 ± 16.89 years; range: 21–76 years
Gender Male 9 (60%)
Female 6 (40%)
Ethnicity Brahmin / Chhetri 5 (33.3%)
Newar 6 (40%)
Tamang 1 (6.7%)
Madhesi 2 (13.3%)
Others 1 (6.7%)
Educational Level No formal education / No Schooling 3 (20.0%)
Primary and Secondary School 4 (26.6%)
College / university 8 (53.3%)
Occupation Not working/ Not employed 1 (6.7%)
Private sector/self-employed 4 (26.7%)
Government sector 2 (13.3%)
Student 2 (13.3%)
Retired 3 (20%)
Housewife 3 (20%)
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questionnaire) and Nepalese LC29 developed for pilot
study.
Observations during pilot testing
Most patients suggested keeping ‘tapai’ instead of ‘hajur’.
Both words give the same meaning i.e. ‘you’, when trans-
lated to English. So we decided to go with the partici-
pants’ preference to maintain consistency in the
questionnaire.
In the sentence, “please go to next page”. Four patients
suggested using ‘pristha’ instead of ‘page’. ‘Pristha’ is
translated as the word ‘page’ in Nepalese language.
Whereas page is translated as the word ‘page’.
(page) and page are pronunciation is the same. In open-
ended question No 60, one patient complained about
bleeding from the nose, one patient complained about
dry skin and no interest in taking food.
Quantitative results
Table 2 shows the pilot testing descriptive results
and comments by patients. The mean and standard
deviation was calculated for item 31 to item 59. Im-
portantly, for all non-surgical items patients used the
entire range of the response options from 1 to 4 and
no missing responses were observed. The five items
of the surgical sub-scale were only applicable to 5 out
of 10 patients, and therefore the number of missing
responses is 10. Among non-surgical items, the high-
est mean (indicating high symptom burden) was ob-
served for the item number. 35 “Have you been short
of breath when you climbed stairs?” (Mean = 3.33,
SD = 1.11) and the lowest mean for item number. 45
“Have you been dizzy?” (Mean = 1.73, SD = 0.96).
Final version of the translated questionnaire
After the results of pilot testing and patient inter-
views were summarized, the problematic items and
wording were changed accordingly. The report of the
EORTC QLQ-LC29’s pilot testing was sent to the
EORTC QoL unit for final approval and to obtain
permission for culturally relevant changes in the ori-
ginal questionnaire—changes that would facilitate its
use in Nepalese cultural settings. The translated full
version of the Nepalese version of the EORTC QLQ
LC-29 is available through the headquarter of the
EORTC QoL Department (https://qol.eortc.org/).
Discussion
This study presented the findings from the transla-
tion of EORTC QLQ-LC29 from English to Nepalese
language and about the cultural adaptation and pilot
testing of the Nepalese version of this QoL measure-
ment tool for patients diagnosed with LC. In this
paper, we report the outcome of a cross-cultural
adaptation and an initial assessment of some basic
distribution properties of the Nepalese version of the
EORTC QLQ-LC29, which is an updated version of
EORTC QLQ-LC13 developed in 1994 [11].
The module QLQ-LC 13 has been translated into
more than sixty languages, and also considered as one
of the standard tool used for assessing QoL in LC pa-
tients [16, 17]. The updated LC module QLQ-LC-29 is
now accessible for use and can be obtained in 9 differ-
ent languages through the permission of the EORTC
QoL Department. The updated QLQ-LC29 module re-
tains 12 of the 13 original LC 13 items and features
new elements that illustrate the effects of targeted
therapy, chemotherapy, radiotherapy, thoracic surgery,
and immunotherapy [12]. The final phase 4 study has
just been published recently [18].
This is the Nepalese version of LC29 which was ap-
proved and reviewed by the team of EORTC, who su-
pervised all the steps in making this Nepalese version.
This study highlights the importance of using a LC-
specific instrument for measuring QOL in this patient
population.
We implemented the recommended EORTC trans-
lation procedures guidelines for translating and val-
idating the Nepalese translation of the LC29
questionnaire [15]. The final finalized translation was
submitted to the EORTC where it was evaluated for
the accuracy in translation as well as the method of
translation. There were a small number of questions
related to the translation which was discussed with
the translators (FT1, FT2, BT1 and BT2) and incor-
porated in the final version, which has been approved
by the EORTC with the requisite copyright and can
now be used in various clinical trials of LC as well as
in routine QoL assessment for Nepalese speaking pa-
tients. The final Nepalese translated version has been
translated in a way that it is culturally appropriate as
well, no culturally inappropriate terms have been used
and substantial consideration was given to make the
sentences generally understandable rather than a pure
focus on translation, for example, the term ‘allergy’
was not translated but was written as allergy in Deva-
nagari script as people in Nepal use allergy in daily
communication than actual translation.
One limitation of this paper that the sample size
was not sufficient to gain data on the performance of
the new questionnaire as a tool for clinical practice
or international clinical studies. To this end, future
large scale trials are needed and such trials also
would allow performing psychometric analysis. A
similar recommendation was spelled out by Marinho
et al. who recently translated the QLQ-LC29 into the
Portuguese language [19, 20].
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Conclusion
In conclusion, the standardized translation procedure
and the pilot testing resulted in an EORTC-approved
Nepalese version of the QLQ-LC29. The accessibility
of this questionnaire in Nepalese adaptation will en-
courage the appraisal of the health-related QoL of LC
patients in Nepal, especially with regards to clinical
research, yet also possibly in the clinical practice set-
tings. Future investigations with a larger sample are
needed to look at the psychometric properties of the
Nepalese version of the EORTC QLQ-LC29 among
patients with lung malignancy and how well the new
module performs in clinical studies and clinical
practice.
Table 2 Pilot testing: Descriptive statistics and comments by patients
Item
No.
Content Response options Missing Mean SD Comments
Not at all
1
A little
2
Quite
a bit
3
Very
much
4
31 Have you coughed? 5 3 3 4 0 2.40 1.24 none
32 Have you coughed up blood? 5 2 3 5 0 1.87 1.06 none
33 Have you been short of breath when you rested? 5 2 3 5 0 2.53 1.30 none
34 Have you been short of breath when you walked? 1 5 1 8 0 3.07 1.10 none
35 Have you been short of breath when you climbed
stairs?
2 1 2 10 0 3.33 1.11 none
36 Have you had a sore mouth or tongue? 6 3 3 3 0 2.20 1.21 none
37 Have you had problems swallowing? 5 4 4 2 0 2.20 1.08 none
38 Have you had tingling hands or feet? 6 3 3 3 0 2.20 1.21 none
39 Have you had hair loss? 7 4 1 3 0 2.00 1.20 none
40 Have you had pain in your chest? 6 3 3 3 0 2.20 1.21 none
41 Have you had pain in your arm or shoulder? 7 3 3 2 0 2.00 1.13 none
42 Have you had pain in other parts of your body? 5 5 2 3 0 2.20 1.15 none
43 Have you had allergic reactions? 7 3 3 2 0 2.00 1.13 none
44 Have you had burning or sore eyes? 4 3 2 6 0 2.67 1.29 none
45 Have you been dizzy? 8 4 2 1 0 1.73 0.96 none
46 Have you had splitting fingernails or toenails? 5 6 2 2 0 2.07 1.03 none
47 Have you had skin problems (e.g. itchy, dry)? 5 2 2 6 0 2.60 1.35 none
48 Have you had problems speaking? 7 2 2 4 0 2.20 1.32 none
49 Have you been afraid of tumor progression? 7 3 3 2 0 2.00 1.13 none
50 Have you had thin or lifeless hair as a result of your
disease or treatment?
6 5 1 3 0 2.07 1.16 none
51 Have you worried’ about your health in the future? 5 5 3 2 0 2.13 1.06 none
52 Have you had dry cough? 5 2 1 7 0 2.67 1.40 none
53 Have you experienced a decrease in your physical
capabilities?
6 3 3 3 0 2.20 1.21 Patients suggested to
keep instead for
to maintain
consistency. Both word
gives same meaning in
Nepalese Language.
54 Has weight loss been a problem for you? 7 3 1 4 0 2.13 1.30 none
55 Have you had pain in the area of surgery? 3 2 – – 10 1.40 0.55 none
56 Has the area of your wound been oversensitive? 3 1 1 – 10 1.60 0.89 none
57 Have you been restricted in your performance
due to the extent of surgery?
4 1 – – 10 1.20 0.45 none
58 Have you had any difficulty using your arm or
shoulder on the side of the chest operation?
3 1 1 – 10 1.60 0.89 none
59 Has your scar pain interfered with your daily
activities?
4 1 – – 10 1.20 0.45 none
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